Ben Braun, MD, PhD
Associate Professor
Pediatrics
School of Medicine

Education & Training

Show all (1) Hide

• M.D. School of Medicine University of California Los Angeles 1998

Websites

Show all (1) Hide

• Clinical Profile at UCSF Benioff Children's Hospital (ucsfbenioffchildrens.org)

Grants and Projects

Show all (3) Hide

• Mechanisms linking RAS signals to disordered hematopoiesis and myeloid neoplasia, NIH, 2013-2018
• Bio-Organic Biomedical Mass Spectrometry Resource, NIH, 1982-2015
• In Vivo Analysis of Oncogenic Kras in Leukemogenesis, NIH, 2005-2010

Publications (47)

Top publication keywords:
Protein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene Proteins p21(ras)ras ProteinsHeterocyclic Compounds, 3-RingCell TrackingHematopoietic Stem CellsMyeloproliferative DisordersDiphenylamineLeukemia, MyeloidLeukemia, Myelomonocytic, JuvenileGRB2 Adaptor ProteinMyelodysplastic SyndromesGenes, rasTime-Lapse ImagingLeukemia, Experimental

• Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes.
  Leukemia 2024 Jann JC, Hergott CB, Winkler M, Liu Y, Braun B, Charles A, Copson KM, Barua S, Meggendorfer M, Nadarajah N, Shimony S, Winer ES, Wadleigh M, Stone RM, DeAngelo DJ, Garcia JS, Haferlach T, Lindsley RC,…
• Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma.
  EJNMMI research 2024 Kumar P, Koach J, Nekritz E, Mukherjee S, Braun BS, DuBois SG, Nasholm N, Haas-Kogan D, Matthay KK, Weiss WA, Gustafson C, Seo Y
• Aurora Kinase A inhibition enhances DNA damage and tumor cell death with 131I-MIBG therapy in high-risk neuroblastoma.
  Research square 2024 Kumar P, Koach J, Nekritz E, Mukherjee S, Braun BS, DuBois SG, Nasholm N, Haas-Kogan D, Matthay KK, Weiss WA, Gustafson C, Seo Y
• Venetoclax and dinaciclib elicit synergistic preclinical efficacy against hypodiploid acute lymphoblastic leukemia.
  Haematologica 2023 Pariury H, Fandel J, Bachl S, Ang KK, Markossian S, Wilson CG, Braun BS, Popescu B, Wohlfeil M, Beckman K, Xirenayi S, Roy RP, Olshen AB, Smith C, Arkin MR, Loh ML, Diaz-Flores E
• Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies.
  Pediatric blood & cancer 2023 Marinoff AE, Aaronson K, Agrawal AK, Braun BS, Golden C, Huang BJ, Michlitsch J, Southworth E, Thrall A, Vo KT, Stieglitz E

Show all (42 more) Hide

• Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia.
  Blood advances 2021 Morales CE, Stieglitz E, Kogan SC, Loh ML, Braun BS
• The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment.
  Haematologica 2021 Tran TH, Nguyen JV, Stecula A, Akutagawa J, Moorman AV, Braun BS, Sali A, Mullighan CG, Shah NP, Dai Y, Devidas M, Roberts KG, Smith CC, Loh ML
• KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice.
  JCI insight 2020 Wong JC, Perez-Mancera PA, Huang TQ, Kim J, Grego-Bessa J, Del Pilar Alzamora M, Kogan SC, Sharir A, Keefe SH, Morales CE, Schanze D, Castel P, Hirose K, Huang GN, Zenker M, Sheppard D, Klein OD, …
• Paroxysmal cold hemoglobinuria successfully treated with complement inhibition.
  Blood advances 2019 Lau-Braunhut SA, Stone H, Collins G, Berentsen S, Braun BS, Zinter MS
• Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing.
  Leukemia 2019 Chao AK, Meyer JA, Lee AG, Hecht A, Tarver T, Van Ziffle J, Koegel AK, Golden C, Braun BS, Sweet-Cordero EA, Smith CC, Dvorak CC, Loh ML, Stieglitz E
• Tissue-Specific Oncogenic Activity of KRASA146T.
  Cancer discovery 2019 Poulin EJ, Bera AK, Lu J, Lin YJ, Strasser SD, Paulo JA, Huang TQ, Morales C, Yan W, Cook J, Nowak JA, Brubaker DK, Joughin BA, Johnson CW, DeStefanis RA, Ghazi PC, Gondi S, Wales TE, Iacob RE, …
• Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia.
  Cancer research 2019 Diaz-Flores E, Comeaux EQ, Kim KL, Melnik E, Beckman K, Davis KL, Wu K, Akutagawa J, Bridges O, Marino R, Wohlfeil M, Braun BS, Mullighan CG, Loh ML
• Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.
  Nature communications 2017 Stieglitz E, Mazor T, Olshen AB, Geng H, Gelston LC, Akutagawa J, Lipka DB, Plass C, Flotho C, Chehab FF, Braun BS, Costello JF, Loh ML
• A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies.
  Cancer research 2017 Maertens O, McCurrach ME, Braun BS, De Raedt T, Epstein I, Huang TQ, Lauchle JO, Lee H, Wu J, Cripe TP, Clapp DW, Ratner N, Shannon K, Cichowski K
• Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.
  Leukemia 2016 Akutagawa J, Huang TQ, Epstein I, Chang T, Quirindongo-Crespo M, Cottonham CL, Dail M, Slusher BS, Friedman LS, Sampath D, Braun BS
• Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
  The Journal of clinical investigation 2016 Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K
• Traxtile: Interactive editing of cell tracks in time-lapse images.
  BioTechniques 2015 Braun BS
• Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.
  Blood 2014 Stieglitz E, Troup CB, Gelston LC, Haliburton J, Chow ED, Yu KB, Akutagawa J, Taylor-Weiner AN, Liu YL, Wang YD, Beckman K, Emanuel PD, Braun BS, Abate A, Gerbing RB, Alonzo TA, Loh ML
• PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.
  Science signaling 2013 Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K
• Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
  The Journal of clinical investigation 2012 Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K
• KIT's ship comes in.
  Blood 2012 Braun BS
• Targeting oncogenic Ras signaling in hematologic malignancies.
  Blood 2012 Ward AF, Braun BS, Shannon KM
• A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
  Science translational medicine 2011 Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS
• Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells.
  Blood 2011 Chan G, Cheung LS, Yang W, Milyavsky M, Sanders AD, Gu S, Hong WX, Liu AX, Wang X, Barbara M, Sharma T, Gavin J, Kutok JL, Iscove NN, Shannon KM, Dick JE, Neel BG, Braun BS
• Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
  Blood 2010 Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K
• Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.
  Nature genetics 2010 Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, Gorr TA, Mehta P, Schmid I, Kropshofer G, Corbacioglu S, Lang PJ, Klein C, Schlegel PG, Heinzmann A, Schneider M…
• Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.
  Proceedings of the National Academy of Sciences of the United States of America 2010 Dail M, Li Q, McDaniel A, Wong J, Akagi K, Huang B, Kang HC, Kogan SC, Shokat K, Wolff L, Braun BS, Shannon K
• The SPS affair: a complex tale of illicit proliferation.
  Cancer cell 2009 Braun BS, Shannon K
• JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal.
  Cancer cell 2009 Santaguida M, Schepers K, King B, Sabnis AJ, Forsberg EC, Attema JL, Braun BS, Passegué E
• Oncogenic Kras initiates leukemia in hematopoietic stem cells.
  PLoS biology 2009 Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS
• Pediatric malignancies: update on sarcomas and leukemia development in children.
  Current opinion in genetics & development 2009 Braun BS, Lessnick SL
• Targeting Ras in myeloid leukemias.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Braun BS, Shannon K
• K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells.
  Blood 2006 Van Meter ME, Díaz-Flores E, Archard JA, Passegué E, Irish JM, Kotecha N, Nolan GP, Shannon K, Braun BS
• Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.
  Blood 2006 Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K
• Inherited predispositions and hyperactive Ras in myeloid leukemogenesis.
  Pediatric blood & cancer 2006 Lauchle JO, Braun BS, Loh ML, Shannon K
• Congenital leukemia cutis with subsequent development of leukemia.
  Journal of the American Academy of Dermatology 2006 Zhang IH, Zane LT, Braun BS, Maize J, Zoger S, Loh ML
• The sum is greater than the FGFR1 partner.
  Cancer cell 2004 Braun BS, Shannon K
• Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.
  Blood 2004 Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, Braun BS, Wang E, Kogan SC, Le Beau MM, Parada L, Shannon KM
• Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.
  Proceedings of the National Academy of Sciences of the United States of America 2003 Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, Le Beau MM, Jacks TE, Shannon KM
• EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic.
  Nature genetics 1997 May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT
• EAT-2 is a novel SH2 domain containing protein that is up regulated by Ewing's sarcoma EWS/FLI1 fusion gene.
  Oncogene 1996 Thompson AD, Braun BS, Arvand A, Stewart SD, May WA, Chen E, Korenberg J, Denny C
• Identification of target genes for the Ewing's sarcoma EWS/FLI fusion protein by representational difference analysis.
  Molecular and cellular biology 1995 Braun BS, Frieden R, Lessnick SL, May WA, Denny CT
• A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1.
  Oncogene 1995 Jeon IS, Davis JN, Braun BS, Sublett JE, Roussel MF, Denny CT, Shapiro DN
• Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene.
  Oncogene 1995 Lessnick SL, Braun BS, Denny CT, May WA
• The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1.
  Molecular and cellular biology 1993 May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, Hromas R, Denny CT
• Prevention of experimental autoimmune arthritis with a peptide fragment of type II collagen.
  European journal of immunology 1993 Ku G, Kronenberg M, Peacock DJ, Tempst P, Banquerigo ML, Braun BS, Reeve JR, Brahn E
• Creation of a yeast artificial chromosome fragmentation vector based on lysine-2.
  Genetic analysis, techniques and applications 1992 Lewis BC, Shah NP, Braun BS, Denny CT